Trials / Completed
CompletedNCT03664804
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
A Multi-Site, Prospective, Longitudinal, Cohort Study Measuring Cerebrospinal Fluid-Mutant Huntingtin Protein in Patients With Huntington's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Study Drug was Administered in this Study | No study drug was administered in this study |
Timeline
- Start date
- 2018-12-05
- Primary completion
- 2021-05-07
- Completion
- 2022-05-07
- First posted
- 2018-09-11
- Last updated
- 2025-01-03
- Results posted
- 2025-01-03
Locations
15 sites across 4 countries: United States, Canada, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT03664804. Inclusion in this directory is not an endorsement.